- In late June 2026, Synopsys, Inc. was removed from several major Russell growth and defensive indices, including the Russell 1000 Growth and Russell 3000 Growth benchmarks, following the latest index reconstitution.
- This broad index removal may prompt substantial trading by passive funds and ETFs, potentially reshaping how Synopsys features in institutional portfolios and benchmark-driven strategies.
- We’ll now examine how Synopsys’s removal from multiple Russell growth and defensive indices could influence its broader investment narrative.
The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.
Synopsys Investment Narrative Recap
To own Synopsys, you need to believe in its role as a core enabler of advanced chip and system design, especially as AI and complex architectures proliferate. The recent removal from multiple Russell growth and defensive indices may create short term trading noise, but it does not directly change the key near term catalyst around Ansys integration, nor the biggest current risk around execution, cost control, and potential margin pressure as that integration and portfolio realignment progress.
The most relevant recent announcement here is Synopsys’ May guidance update, which lifted full year revenue expectations to US$9,625 million to US$9,705 million and reiterated its focus on integrating Ansys while managing divestitures and restructuring. This guidance sits alongside a 10 percent global headcount reduction and portfolio realignment that are central to the margin recovery story, but also underline the execution and financial complexity risks that shareholders now need to weigh more carefully.
Yet behind the index changes, investors should still be aware of how Ansys integration and the related headcount cuts could...
Read the full narrative on Synopsys (it's free!)
Synopsys' narrative projects $12.5 billion revenue and $2.0 billion earnings by 2029.
Uncover how Synopsys' forecasts yield a $559.58 fair value, a 27% upside to its current price.
Exploring Other Perspectives
Three Simply Wall St Community valuations cluster between about US$495 and US$560 per share, suggesting a fairly tight range of retail expectations. You can compare those views with the execution and integration risks around Ansys that could influence how Synopsys actually performs over time, and decide which perspectives you find most convincing.
Explore 3 other fair value estimates on Synopsys - why the stock might be worth just $495.35!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Synopsys research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Synopsys research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Synopsys' overall financial health at a glance.
Contemplating Other Strategies?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com